Postchemotherapy residual masses (rm) in testicular nonseminomatous germ cell tumor (TNSGCT): Role of prognostic factors and adjuvant chemotherapy

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4662-4662
Author(s):  
A. P. Fraccon ◽  
T. Sava ◽  
G. Martignoni ◽  
S. Pessa ◽  
M. Frisinghelli ◽  
...  
2012 ◽  
Vol 10 (3) ◽  
pp. 185-189 ◽  
Author(s):  
Meltem Ekenel ◽  
Serkan Keskin ◽  
Öner Şanli ◽  
Sevil Bavbek ◽  
Murat Tunç ◽  
...  

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 390-390
Author(s):  
Shi-Ming Tu ◽  
Mehmet Asim Bilen ◽  
Zachary H. Tu ◽  
Raphael General ◽  
John Francis Ward ◽  
...  

390 Background: Cancer is a heterogeneous disease. Studying cancer heterogeneity may enable us to elucidate the various subtypes of a particular cancer, and improve the diagnosis, prognostication, and therapy of cancer. Nonseminomatous germ cell tumor (NSGCT) is a prime example of a heterogeneous disease. We determined potential lethality of NSGCT by characterizing the histological makeup of primary testicular tumors, the tumor burden, psychosocial issues, and surgical factors. Methods: From November 1997 to October 2012, 142 consecutive patients diagnosed with a NSGCT of the testis were evaluated for this study. The log-rank test was used to identify prognostic factors in univariate Kaplan-Meier analysis. A multivariate Cox regression model was used to evaluate predictive factors for overall survival. Results: Patient and tumor characteristics: median (range) age 25 (12 to 53); pathology – embryonal carcinoma 15%, teratoma 6%, and mixed NSGCT 79%; stage – I 46%, II 32%, and III 21%. Ten (7%) patients died from their NSGCT. Seven (5%) patients had incurable NSGCT. Multivariate analysis showed that presence of seminoma (p=0.007), presence of yolk sac tumor (p=0.019), clinical stage (p=0.027), and psychosocial issues (p=0.04), have unfavorable prognostic significance. Conclusions: Certain subtypes of NSGCT containing yolk sac tumor and seminoma are inherently chemotherapy resistant and potentially lethal. Psychosocial factors can delay the diagnosis and treatment of patients with such tumors and adversely affect their clinical outcome. Results of this study need to be validated in another data base or a prospective clinical trial.


1992 ◽  
Vol 61 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Willem E. de Graaff ◽  
J. Wolter Oosterhuis ◽  
Bauke de Jong ◽  
Jannie van Echten-Arends ◽  
Janneke Wiersema-Buist ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document